- Home
- NML vs ERAS Comparison
NML vs ERAS Comparison
Compare NML & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- ERAS
- Stock Information
- Founded
- NML 2012
- ERAS 2018
- Country
- NML United States
- ERAS United States
- Employees
- NML N/A
- ERAS N/A
- Industry
- NML Finance/Investors Services
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- NML Finance
- ERAS Health Care
- Exchange
- NML Nasdaq
- ERAS Nasdaq
- Market Cap
- NML 487.3M
- ERAS 484.4M
- IPO Year
- NML N/A
- ERAS 2021
- Fundamental
- Price
- NML $8.66
- ERAS $1.46
- Analyst Decision
- NML
- ERAS Strong Buy
- Analyst Count
- NML 0
- ERAS 6
- Target Price
- NML N/A
- ERAS $4.83
- AVG Volume (30 Days)
- NML 219.3K
- ERAS 785.4K
- Earning Date
- NML 01-01-0001
- ERAS 08-19-2025
- Dividend Yield
- NML 9.75%
- ERAS N/A
- EPS Growth
- NML N/A
- ERAS N/A
- EPS
- NML N/A
- ERAS N/A
- Revenue
- NML N/A
- ERAS N/A
- Revenue This Year
- NML N/A
- ERAS N/A
- Revenue Next Year
- NML N/A
- ERAS N/A
- P/E Ratio
- NML N/A
- ERAS N/A
- Revenue Growth
- NML N/A
- ERAS N/A
- 52 Week Low
- NML $6.09
- ERAS $1.01
- 52 Week High
- NML $7.33
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- NML 46.88
- ERAS 47.61
- Support Level
- NML $8.56
- ERAS $1.34
- Resistance Level
- NML $8.80
- ERAS $1.54
- Average True Range (ATR)
- NML 0.14
- ERAS 0.12
- MACD
- NML 0.01
- ERAS -0.02
- Stochastic Oscillator
- NML 52.94
- ERAS 25.53
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.